Browse by UCL people
Group by: Type | Date
Number of items: 41.
2026
Macnair, Archie;
Gilbert, Duncan C;
Nankivell, Matthew;
Joharatnam Hogan, Nalinie;
Hullock, Katie;
Radice, Domenico;
Meade, Angela;
... Cafferty, Fay H; + view all
(2026)
Healthcare systems data (HSD) to improve the efficiency of clinical trials within the UK: A prospectively planned comparison of HSD and trial-reported outcomes within the Add-Aspirin cancer clinical trial.
Clinical Oncology
, Article 104059. 10.1016/j.clon.2026.104059.
(In press).
|
 |
2025
|
Bouche, Gauthier;
Gilbert, Duncan;
Quartagno, Matteo;
Dehbi, Hakim-Moulay;
Merrick, Sophie;
Barjesteh van Waalwijk van Doorn-Khosrovani, Sahar;
Stephens, Richard;
... Langley, Ruth E; + view all
(2025)
Determining the optimal use of approved drugs in oncology.
The Lancet Oncology
, 26
(5)
e282-e294.
10.1016/S1470-2045(25)00037-3.
|
2024
|
Samuel, Robert J;
Gilbert, Duncan C;
(2024)
Understanding the molecular biology of anal squamous cell carcinoma.
International Journal of Cancer
, 154
(3)
pp. 410-411.
10.1002/ijc.34782.
|
|
Sinclair, H;
Ranji, T;
Gilbert, DC;
(2024)
Will Immune Checkpoint Inhibitors Allow the Non-operative Management of Mismatch Repair-deficient Colorectal Cancer to Become a Standard of Care?
Clinical Oncology
10.1016/j.clon.2024.01.006.
(In press).
|
|
Sydes, Matthew R;
Murray, Macey L;
Ahmed, Saiam;
Apostolidou, Sophia;
Bliss, Judith M;
Bloomfield, Claire;
Cannings-John, Rebecca;
... Love, Sharon B; + view all
(2024)
Getting our ducks in a row: The need for data utility comparisons of healthcare systems data for clinical trials.
Contemporary Clinical Trials
, 141
, Article 107514. 10.1016/j.cct.2024.107514.
|
|
2023
|
Bouche, Gauthier;
Langley, Ruth;
Rush, Hannah;
Parmar, Mahesh;
Gilbert, Duncan C;
(2023)
Testing alternative schedules of adjuvant Immune checkpoint Blockers – the need for well-designed clinical trials.
European Journal of Cancer
, 178
pp. 88-90.
10.1016/j.ejca.2022.10.024.
|
|
Gilbert, DC;
Nankivell, M;
Rush, H;
Clarke, NW;
Mangar, S;
Al-Hasso, A;
Rosen, S;
... Langley, RE; + view all
(2023)
A Repurposing Programme Evaluating Repurposing Transdermal Oestradiol Patches for the Treatment of Prostate Cancer Within the PATCH and STAMPEDE Trials: Current Results and Adapting Trial Design.
Clinical Oncology
10.1016/j.clon.2023.10.054.
(In press).
|
|
Macnair, Archie;
Nankivell, Matthew;
Murray, Macey L;
Rosen, Stuart D;
Appleyard, Sally;
Sydes, Matthew R;
Forcat, Sylvia;
... Gilbert, Duncan C; + view all
(2023)
Healthcare systems data in the context of clinical trials - A comparison of cardiovascular data from a clinical trial dataset with routinely collected data.
Contemporary Clinical Trials
, 128
, Article 107162. 10.1016/j.cct.2023.107162.
|
|
Overbeek, JK;
Heine, RT;
Verheul, HMW;
Chatelut, E;
Rudek, MA;
Gurney, H;
Plummer, R;
... van Erp, NP; + view all
(2023)
Off-label, but on target: the evidence needed to implement alternative dosing regimens of anticancer drugs.
ESMO Open
, 8
(1)
, Article 100749. 10.1016/j.esmoop.2022.100749.
|
|
Robinson, SD;
Samuels, M;
Jones, W;
Gilbert, D;
Critchley, G;
Giamas, G;
(2023)
Shooting the messenger: a systematic review investigating extracellular vesicle isolation and characterisation methods and their influence on understanding extracellular vesicles-radiotherapy interactions in glioblastoma.
BMC Cancer
, 23
, Article 939. 10.1186/s12885-023-11437-6.
|
|
Samuel, R;
Samson, A;
Gilbert, DC;
(2023)
Improving Outcomes with Chemoradiotherapy in the Mucosal Squamous Cell Carcinomas – Immune Checkpoint Inhibition and Broken Promises.
Clinical Oncology
, 35
(12)
pp. 764-768.
10.1016/j.clon.2023.09.003.
|
|
Sodergren, SC;
Johnson, CD;
Gilbert, A;
Darlington, AS;
Cocks, K;
Guren, MG;
Rivin del Campo, E;
... Vassiliou, V; + view all
(2023)
International Validation of the EORTC QLQ-ANL27, a Field Study to Test the Anal Cancer-Specific Health-Related Quality-of-Life Questionnaire.
International Journal of Radiation Oncology Biology Physics
, 115
(5)
pp. 1155-1164.
10.1016/j.ijrobp.2022.11.002.
|
2022
|
Hirsch, Ian;
Goldstein, Daniel A;
Tannock, Ian F;
Butler, Marcus O;
Gilbert, Duncan C;
(2022)
Optimizing the dose and schedule of immune checkpoint inhibitors in cancer to allow global access.
Nature Medicine
, 28
pp. 2236-2237.
10.1038/s41591-022-02029-1.
|
|
James, Nicholas D;
Clarke, Noel W;
Cook, Adrian;
Ali, Adnan;
Hoyle, Alex P;
Attard, Gert;
Brawley, Chris D;
... Sydes, Matthew R; + view all
(2022)
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).
International Journal of Cancer
, 151
(3)
pp. 422-434.
10.1002/ijc.34018.
|
|
Parker, Chris C;
James, Nicholas D;
Brawley, Christopher D;
Clarke, Noel W;
Ali, Adnan;
Amos, Claire L;
Attard, Gerhardt;
... Sydes, Matthew R; + view all
(2022)
Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial.
PLoS Medicine
, 19
(6)
, Article e1003998. 10.1371/journal.pmed.1003998.
|
|
Stewart, E;
Tavabie, S;
White, N;
Appleyard, S;
Bass, S;
Gilbert, D;
Herriott, R;
... Minton, O; + view all
(2022)
A short report examining the introduction of routine use of patient reported outcome measures in a mixed oncology population.
Clinical Oncology
, 34
(4)
pp. 241-246.
10.1016/j.clon.2021.11.016.
|
2021
|
Appleyard, SE;
Larkin, MJW;
Stewart, EM;
Minton, O;
Gilbert, DC;
(2021)
Digital Medicine in Men with Advanced Prostate Cancer – A Feasibility Study of Electronic Patient-reported Outcomes in Patients on Systemic Treatment.
Clinical Oncology
, 33
(12)
pp. 751-760.
10.1016/j.clon.2021.04.008.
|
|
Attard, G;
Murphy, L;
Clarke, NW;
Cross, W;
Jones, RJ;
Parker, CC;
Gillessen, S;
... Systemic Therapy in Advancing or Metastatic Prostate cancer: Eva; + view all
(2021)
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
The Lancet
10.1016/S0140-6736(21)02437-5.
(In press).
|
|
Gilbert, DC;
Speirs, V;
(2021)
Biobanking in radiotherapy trials - a challenge to the clinical research community.
Nature Reviews Clinical Oncology
, 18
(4)
pp. 191-192.
10.1038/s41571-021-00486-0.
|
|
Langley, RE;
Gilbert, DC;
Duong, T;
Clarke, NW;
Nankivell, M;
Rosen, SD;
Mangar, S;
... Parmar, M; + view all
(2021)
Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme.
The Lancet
, 397
(10274)
pp. 581-591.
10.1016/s0140-6736(21)00100-8.
|
|
Macnair, A;
Love, SB;
Murray, ML;
Gilbert, DC;
Parmar, MKB;
Denwood, T;
Carpenter, J;
... Cafferty, FH; + view all
(2021)
Accessing routinely collected health data to improve clinical trials: recent experience of access.
Trials
, 22
, Article 340. 10.1186/s13063-021-05295-5.
|
|
|
Obermueller, T;
Hautekiet, J;
Busto, MP;
Reynders, D;
Belgioia, L;
Cats, A;
Gilbert, DC;
... Prigge, ES; + view all
(2021)
Prognostic value of high-risk human papillomavirus DNA and p16INK4a immunohistochemistry in patients with anal cancer: An individual patient data meta-analysis.
European Journal of Cancer
, 157
pp. 165-178.
10.1016/j.ejca.2021.07.041.
|
|
Rush, HL;
Murphy, L;
Morgans, AK;
Clarke, NW;
Cook, AD;
Attard, G;
Macnair, A;
... Langley, RE; + view all
(2021)
Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial.
Journal of Clinical Oncology
10.1200/JCO.21.00728.
(In press).
|
|
|
Wakeham, K;
Murray, L;
Muirhead, R;
Hawkins, MA;
Sebag-Montefiore, D;
Brown, S;
Murphy, L;
... Gilbert, DC; + view all
(2021)
Multicentre Investigation of Prognostic Factors Incorporating p16 and Tumour Infiltrating Lymphocytes for Anal Cancer After Chemoradiotherapy.
Clinical Oncology
10.1016/j.clon.2021.04.015.
(In press).
|
|
|
Ward, TH;
Gilbert, DC;
Higginbotham, G;
Morris, CM;
Speirs, V;
Curtin, NJ;
(2021)
Radiotherapy biobanking: current landscape, opportunities, challenges, and future aspirations.
Journal of Pathology: Clinical Research
10.1002/cjp2.246.
(In press).
|
|
2020
|
Clarke, NW;
Ali, A;
Ingleby, FC;
Hoyle, A;
Amos, CL;
Attard, G;
Brawley, CD;
... STAMPEDE investigators; + view all
(2020)
Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992-2003.
[Corrigendum].
Annals of Oncology
, 31
(3)
p. 442.
10.1016/j.annonc.2020.01.002.
|
|
|
Gilbert, A;
Drinkwater, K;
McParland, L;
Adams, R;
Glynne-Jones, R;
Harrison, M;
Hawkins, MA;
... Muirhead, R; + view all
(2020)
UK national cohort of anal cancer treated with intensity-modulated radiotherapy: One-year oncological and patient-reported outcomes.
European Journal of Cancer
, 128
pp. 7-16.
10.1016/j.ejca.2019.12.022.
|
|
Gilson, C;
Ingleby, F;
Gilbert, DC;
Parry, MA;
Atako, NB;
Ali, A;
Hoyle, A;
... Chowdhury, S; + view all
(2020)
Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial.
JCO Precision Oncology
, 4
pp. 882-897.
10.1200/po.19.00388.
|
|
Jones, H;
Gilbert, D;
Gilbert, A;
Jacobs, C;
Muirhead, R;
(2020)
DPD testing in radical chemoradiation for anal squamous cell carcinoma.
Annals of Oncology
, 31
(11)
p. 1580.
10.1016/j.annonc.2020.07.015.
|
|
Lee, JY;
Cutts, RJ;
White, I;
Augustin, Y;
Garcia-Murillas, I;
Fenwick, K;
Matthews, N;
... Bhide, S; + view all
(2020)
Next Generation Sequencing Assay for Detection of Circulating HPV DNA (cHPV-DNA) in Patients Undergoing Radical (Chemo)Radiotherapy in Anal Squamous Cell Carcinoma (ASCC).
Frontiers in Oncology
, 10
, Article 505. 10.3389/fonc.2020.00505.
|
|
|
Lee, LYW;
Cazier, J-B;
Starkey, T;
Briggs, SEW;
Arnold, R;
Bisht, V;
Booth, S;
... UK Coronavirus Cancer Monitoring Project Team; + view all
(2020)
COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study.
The Lancet Oncology
, 21
(10)
pp. 1309-1316.
10.1016/S1470-2045(20)30442-3.
|
|
O'Cathail, SM;
Gilbert, DC;
Sebag-Montefiore, D;
Muirhead, R;
(2020)
Challenges and Consequences of COVID-19 in the Management of Anorectal Cancer: Coming Together Through Social Distancing.
Clinical Oncology
, 32
(7)
pp. 413-416.
10.1016/j.clon.2020.04.009.
|
|
|
Shakir, R;
Adams, R;
Cooper, R;
Downing, A;
Geh, I;
Gilbert, D;
Jacobs, C;
... Muirhead, R; + view all
(2020)
Patterns and Predictors of Relapse Following Radical Chemoradiation Therapy Delivered Using Intensity Modulated Radiation Therapy With a Simultaneous Integrated Boost in Anal Squamous Cell Carcinoma.
International Journal of Radiation Oncology*Biology*Physics
, 106
(2)
pp. 329-339.
10.1016/j.ijrobp.2019.10.016.
|
|
2019
|
Clarke, NW;
Ali, A;
Ingleby, FC;
Hoyle, A;
Amos, CL;
Attard, G;
Brawley, CD;
... James, ND; + view all
(2019)
Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial.
Annals of Oncology
10.1093/annonc/mdz396.
(In press).
|
|
Gilbert, DC;
Vale, CL;
(2019)
Reply to Comments on "Increased risk of second cancers at sites associated with HPV after a prior HPV-associated malignancy, a systematic review and meta-analysis".
British Journal of Cancer
, 120
, Article 956. 10.1038/s41416-019-0440-7.
|
|
Gilbert, DC;
Wakeham, K;
Langley, RE;
Vale, CL;
(2019)
Increased risk of second cancers at sites associated with HPV after a prior HPV-associated malignancy, a systematic review and meta-analysi.
British Journal of Cancer
, 120
(2)
pp. 256-268.
10.1038/s41416-018-0273-9.
|
|
Joharatnam-Hogan, N;
Cafferty, F;
Hubner, R;
Swinson, D;
Sothi, S;
Gupta, K;
Falk, S;
... Add-Aspirin Trial Management Group; + view all
(2019)
Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trial.
The Lancet Gastroenterology & Hepatology
, 4
(11)
pp. 854-862.
10.1016/S2468-1253(19)30289-4.
|
2018
|
Gilbert, DC;
Duong, T;
Sydes, M;
Bara, A;
Clarke, N;
Abel, P;
James, N;
... STAMPEDE and PATCH Trial Management Groups, .; + view all
(2018)
Transdermal oestradiol as a method of androgen suppression for prostate cancer within the STAMPEDE trial platform.
BJU International
, 121
(5)
pp. 680-683.
10.1111/bju.14153.
|
|
Sydes, MR;
(2018)
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol.
Annals Of Oncology
, 29
(5)
pp. 1235-1248.
10.1093/annonc/mdy072.
|
|
2017
|
Gilbert, DC;
Duong, T;
Kynaston, HG;
Alhasso, AA;
Cafferty, FH;
Rosen, SD;
Kanaga-Sundaram, S;
... Abel, PD; + view all
(2017)
Quality of life outcomes from the PATCH trial evaluating LHRH agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer.
BJU International
, 119
(5)
pp. 667-675.
10.1111/bju.13687.
|
2016
|
Coyle, C;
Cafferty, FH;
Rowley, S;
MacKenzie, M;
Berkman, L;
Gupta, S;
Pramesh, CS;
... Langley, RE; + view all
(2016)
ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours.
Contemporary Clinical Trials
, 51
pp. 56-64.
10.1016/j.cct.2016.10.004.
|
